These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

486 related items for PubMed ID: 12766987

  • 1. Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy.
    Winkel LP, Kamphoven JH, van den Hout HJ, Severijnen LA, van Doorn PA, Reuser AJ, van der Ploeg AT.
    Muscle Nerve; 2003 Jun; 27(6):743-51. PubMed ID: 12766987
    [Abstract] [Full Text] [Related]

  • 2. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up.
    Winkel LP, Van den Hout JM, Kamphoven JH, Disseldorp JA, Remmerswaal M, Arts WF, Loonen MC, Vulto AG, Van Doorn PA, De Jong G, Hop W, Smit GP, Shapira SK, Boer MA, van Diggelen OP, Reuser AJ, Van der Ploeg AT.
    Ann Neurol; 2004 Apr; 55(4):495-502. PubMed ID: 15048888
    [Abstract] [Full Text] [Related]

  • 3. [Pompe's disease. Part II. Treatment strategies and enzyme replacement].
    Illés Z, Várdi Visy K.
    Ideggyogy Sz; 2009 Sep 30; 62(9-10):299-307. PubMed ID: 19835271
    [Abstract] [Full Text] [Related]

  • 4. [Enzyme replacement therapy in Pompe's disease].
    Merk T, Wibmer T, Schumann C, Krüger S.
    Med Klin (Munich); 2007 Jul 15; 102(7):570-3. PubMed ID: 17634875
    [Abstract] [Full Text] [Related]

  • 5. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy.
    van der Beek NA, Hagemans ML, van der Ploeg AT, Reuser AJ, van Doorn PA.
    Acta Neurol Belg; 2006 Jun 15; 106(2):82-6. PubMed ID: 16898258
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial.
    Klinge L, Straub V, Neudorf U, Schaper J, Bosbach T, Görlinger K, Wallot M, Richards S, Voit T.
    Neuromuscul Disord; 2005 Jan 15; 15(1):24-31. PubMed ID: 15639117
    [Abstract] [Full Text] [Related]

  • 7. Severe course of glycogen storage disease type II (Pompe's disease) without development of cardiomegalia.
    Ullrich K, Gröbe H, Korinthenberg R, von Bassewitz DB.
    Pathol Res Pract; 1986 Oct 15; 181(5):627-32. PubMed ID: 2947052
    [Abstract] [Full Text] [Related]

  • 8. Pathological features of glycogen storage disease type II highlighted in the knockout mouse model.
    Bijvoet AG, Van Hirtum H, Vermey M, Van Leenen D, Van Der Ploeg AT, Mooi WJ, Reuser AJ.
    J Pathol; 1999 Nov 15; 189(3):416-24. PubMed ID: 10547605
    [Abstract] [Full Text] [Related]

  • 9. [A retrospective study of six patients with late-onset Pompe disease].
    Saux A, Laforet P, Pagès AM, Figarella-Branger D, Pellissier JF, Pagès M, Labauge P.
    Rev Neurol (Paris); 2008 Apr 15; 164(4):336-42. PubMed ID: 18439925
    [Abstract] [Full Text] [Related]

  • 10. Enzyme replacement therapy in severe adult-onset glycogen storage disease type II.
    Ravaglia S, Danesino C, Pichiecchio A, Repetto A, Poloni GU, Rossi M, Fratino P, Moglia A, Costa A.
    Adv Ther; 2008 Aug 15; 25(8):820-9. PubMed ID: 18704279
    [Abstract] [Full Text] [Related]

  • 11. Infantile acid maltase deficiency. II. Muscle fiber hypertrophy and the ultrastructure of end-stage fibers.
    Griffin JL.
    Virchows Arch B Cell Pathol Incl Mol Pathol; 1984 Aug 15; 45(1):37-50. PubMed ID: 6199886
    [Abstract] [Full Text] [Related]

  • 12. Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study.
    Klinge L, Straub V, Neudorf U, Voit T.
    Neuropediatrics; 2005 Feb 15; 36(1):6-11. PubMed ID: 15776317
    [Abstract] [Full Text] [Related]

  • 13. Adeno-associated virus-mediated transfer of human acid maltase gene results in a transient reduction of glycogen accumulation in muscle of Japanese quail with acid maltase deficiency.
    Lin CY, Ho CH, Hsieh YH, Kikuchi T.
    Gene Ther; 2002 May 15; 9(9):554-63. PubMed ID: 11973631
    [Abstract] [Full Text] [Related]

  • 14. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
    Raben N, Fukuda T, Gilbert AL, de Jong D, Thurberg BL, Mattaliano RJ, Meikle P, Hopwood JJ, Nagashima K, Nagaraju K, Plotz PH.
    Mol Ther; 2005 Jan 15; 11(1):48-56. PubMed ID: 15585405
    [Abstract] [Full Text] [Related]

  • 15. Monitoring cardiac function by B-type natriuretic peptide (BNP) in patients with infantile Pompe's disease treated with recombinant alpha-glucosidase.
    Hahn A, Schmidt D, Hagel KJ, Neubauer BA, Katz N.
    Clin Lab; 2006 Jan 15; 52(11-12):615-9. PubMed ID: 17175893
    [Abstract] [Full Text] [Related]

  • 16. Late-onset Pompe's disease.
    Teener JW.
    Semin Neurol; 2012 Nov 15; 32(5):506-11. PubMed ID: 23677658
    [Abstract] [Full Text] [Related]

  • 17. [Pompe's disease. Part I: pathogenesis and clinical features].
    Illés Z, Trauninger A.
    Ideggyogy Sz; 2009 Jul 30; 62(7-8):231-43. PubMed ID: 19685701
    [Abstract] [Full Text] [Related]

  • 18. Long-term enzyme replacement therapy for pompe disease with recombinant human alpha-glucosidase derived from chinese hamster ovary cells.
    Rossi M, Parenti G, Della Casa R, Romano A, Mansi G, Agovino T, Rosapepe F, Vosa C, Del Giudice E, Andria G.
    J Child Neurol; 2007 May 30; 22(5):565-73. PubMed ID: 17690063
    [Abstract] [Full Text] [Related]

  • 19. Late form of Pompe disease with glycogen storage in peripheral nerves axons.
    Fidziańska A, Ługowska A, Tylki-Szymańska A.
    J Neurol Sci; 2011 Feb 15; 301(1-2):59-62. PubMed ID: 21109266
    [Abstract] [Full Text] [Related]

  • 20. Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail.
    Kikuchi T, Yang HW, Pennybacker M, Ichihara N, Mizutani M, Van Hove JL, Chen YT.
    J Clin Invest; 1998 Feb 15; 101(4):827-33. PubMed ID: 9466978
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.